Gallbladder cancer of two histological origins: A case report and review of literature

Omran, Aqdas A Al; Alkhalifa, Abdullah M; AlQattan, Abdullah Saleh; Alshahrani, Abdullah

doi:10.1016/j.ijscr.2021.105704

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another case reported by Varshney et al (14), gemcitabine and cisplatin were administrated following the radical cholecystectomy for GBCS, and the patient achieved progression-free of disease for 6 months. Radiotherapy seemed to be a promising postoperative adjuvant therapy, although its survival benefits were based on limited evidence (15). Since targeted therapy plays an important role in the adjuvant setting, it is also included as part of adjuvant therapeutic regimes for GBCS.…”

Section: Discussionmentioning

confidence: 99%

Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review

et al. 2022

View full text Add to dashboard Cite

BackgroundGallbladder carcinosarcoma (GBCS) is a rare and aggressive malignancy with extremely poor prognosis. Although surgery is regarded as the primary therapy for GBCS, the effective therapeutic strategies for unresected lesions have been poorly defined.Case PresentationWe presented a case of a 74-year-old male who underwent radical resection of gallbladder carcinoma at a local hospital. Seven months later, he was admitted to our hospital due to right upper abdominal discomfort. Postoperative radiological examinations showed multiple hepatic lesions, hilar lymph node metastasis, and main portal vein tumor thrombus. The pathological consultation results confirmed GBCS and immunohistochemical examinations revealed PD-L1 expression in 20% of tumor cells. Then, the patient received chemotherapy (Gemcitabine plus Oxaliplatin, GEMOX) in combination with anti-PD-1 therapy. After nine courses of the combination therapy, complete regression of the tumors was achieved with no evidence of relapse till now.ConclusionsWe, for the first time, reported a patient with recurrent GBCS who benefited from the combined chemotherapy and immunotherapy, providing a potential effective management strategy for the refractory malignant tumor.

show abstract

Section: Discussionmentioning

confidence: 99%